Search research articles
Contact Us
Filters
Showing results (151-160 of 172) with videos related to
Page
of 18
Sort By:
American Journal of Obstetrics and Gynecology
|
April 1, 1994
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
W J Hoskins, W P McGuire, M F Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 9, 2002
FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival
S Memarzadeh, C H Holschneider, R E Bristow, et al.
British Journal of Cancer
|
May 24, 2007
The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients
J K Chan, R Urban, J M Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study
W P McGuire, W J Hoskins, M F Brady, et al.
Cancer Research
|
September 1, 1985
Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
J S Berek, N F Hacker, A Lichtenstein, et al.
American Journal of Obstetrics and Gynecology
|
August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum
J S Berek, R C Knapp, N F Hacker, et al.
American Journal of Obstetrics and Gynecology
|
July 1, 1986
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
J M Niloff, R C Knapp, P T Lavin, et al.
Experimental Cell Research
|
August 1, 1993
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells
Y J Lidor, F J Xu, O Martínez-Maza, et al.
Cancer Treatment Reviews
|
December 1, 1985
Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer
J S Berek, N F Hacker, A Lichtenstein, et al.
Cancer Research
|
March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum
R C Bast, J S Berek, R Obrist, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 172) with videos related to
Sort By:
Page
of 18
American Journal of Obstetrics and Gynecology
|
April 1, 1994
The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma
W J Hoskins, W P McGuire, M F Brady, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
October 9, 2002
FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival
S Memarzadeh, C H Holschneider, R E Bristow, et al.
British Journal of Cancer
|
May 24, 2007
The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients
J K Chan, R Urban, J M Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 1, 1995
Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study
W P McGuire, W J Hoskins, M F Brady, et al.
Cancer Research
|
September 1, 1985
Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study
J S Berek, N F Hacker, A Lichtenstein, et al.
American Journal of Obstetrics and Gynecology
|
August 15, 1985
Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum
J S Berek, R C Knapp, N F Hacker, et al.
American Journal of Obstetrics and Gynecology
|
July 1, 1986
The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer
J M Niloff, R C Knapp, P T Lavin, et al.
Experimental Cell Research
|
August 1, 1993
Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells
Y J Lidor, F J Xu, O Martínez-Maza, et al.
Cancer Treatment Reviews
|
December 1, 1985
Intraperitoneal recombinant alpha 2-interferon for 'salvage' immunotherapy in persistent epithelial ovarian cancer
J S Berek, N F Hacker, A Lichtenstein, et al.
Cancer Research
|
March 1, 1983
Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum
R C Bast, J S Berek, R Obrist, et al.
Page
of 18